Medical University of South Carolina
Hematology and Oncology fellowship · Charleston, SC · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is Medical University of South Carolina's research in hematology and oncology, which the program shares with other departments and affiliated hospitals.
About Medical University of South Carolinainstitution-wide hematology and oncology research
Hematology and Oncology publications from Medical University of South Carolina and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
135
works per year
36th of 74 hematology and oncology fellowship programs
+19.0%
2-year growth
25th of 74 hematology and oncology fellowship programs
25.1%
in top 10% of field (works before 2025)
31st of 72 hematology and oncology fellowship programs
44.1%
cited above world average
32nd of 72 hematology and oncology fellowship programs
Works per year · * 2026 so far
Oncology · 459Hematology · 218
Hematology and Oncology research topics at Medical University of South Carolina
Papers in the window; each links to the list on OpenAlex.
- CAR-T cell therapy research 88
- Multiple Myeloma Research and Treatments 76
- Cancer Immunotherapy and Biomarkers 64
- Hematopoietic Stem Cell Transplantation 55
- Acute Myeloid Leukemia Research 42
- Cancer survivorship and care 40
- Pancreatic and Hepatic Oncology Research 30
- Global Cancer Incidence and Screening 30
Most cited at Medical University of South Carolina since 2024
All hematology and oncology papers there on OpenAlex
- Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trialBradley J. Monk et al. · Annals of Oncology · 2024 · PubMed · cited 197
- 3D genomic mapping reveals multifocality of human pancreatic precancersAlicia M. Braxton et al. · Nature · 2024 · PubMed · cited 158
- Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple MyelomaNico Gagelmann et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 93
- AGA Clinical Practice Update on Management of Iron Deficiency Anemia: Expert ReviewThomas G. DeLoughery et al. · Clinical Gastroenterology and Hepatology · 2024 · PubMed · cited 92
- Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialAlexander Gerhard Miethke et al. · The Lancet. Gastroenterology & hepatology · 2024 · PubMed · cited 78
- Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and TreatmentBruce L. Zuraw et al. · Clinical Reviews in Allergy & Immunology · 2025 · PubMed · cited 73
- Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocolsTricia R. Cottrell et al. · Journal for ImmunoTherapy of Cancer · 2025 · PubMed · cited 61
- Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple MyelomaDoris K. Hansen et al. · Journal of Clinical Oncology · 2025 · PubMed · cited 60
- Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar et al. · Journal of Hematology & Oncology · 2024 · PubMed · cited 59
- Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell TherapyDanai Dima et al. · Blood Cancer Journal · 2024 · PubMed · cited 57